Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH)

• Autor(a) principal: Pinto, Anna Camilla Ferreira Lopes Valério
• Data de Publicação: 2021
• Outros Autores: Medeiros Filho, Osman Batista de, Sousa, Milena Nunes Alves de, Lins, Hugo David Maia Nascimento
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/18921
• topic: Hepatopatia Gordurosa não Alcoólica; Tratamento Farmacológico; Liraglutida.; Non-alcoholic Fatty Liver Disease; Drug Therapy; Liraglutide.; Enfermedad del hígado graso no alcohólico; Quimioterapia; Liraglutida.

To evaluate the effects of liraglutide administration on NASH. Consists of a systematic review of the literature in the main virtual libraries: US National Library of Medicine National Institutes of Health (PubMed), Biblioteca Virtual de Saúde (BVS), Scientific Electronic Library Online (SCIELO) and Latin American and Caribbean Literature in Health Sciences (LILACS) in the last five years, admitting articles from clinical trials. Liraglutide is an analogue of the glacagon 1-like peptide hormone (GLP-1) that acts in suppressing appetite and de novo lipogenesis (DNL), decreasing glucagon release, increasing insulin release and sensitization, among others. For these reasons, its fronts to combat NASH range from the reduction and control of the lipid profile, to the repair of hepatocytes. Currently, with the obesogenic environment found in society, drug therapy has become a great ally of the medical community, as well as in facilitating goals for the patient. The use of liraglutide in NASH proved to be effective in slowing and resolving it, with therapies ranging from 26 to 48 weeks and doses ranging from 0,9 mg to 3,0 mg.